TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.
Saved in:
| Title: | TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients. |
|---|---|
| Authors: | Vicier, Cecile1,2 (AUTHOR), Sfumato, Patrick3 (AUTHOR), Isambert, Nicolas4 (AUTHOR), Dalenc, Florence5 (AUTHOR), Robert, Marie6 (AUTHOR), Levy, Christelle7 (AUTHOR), Rezai, Keyvan8 (AUTHOR), Provansal, Magali1 (AUTHOR), Adélaïde, José2 (AUTHOR), Garnier, Séverine2 (AUTHOR), Guille, Arnaud2 (AUTHOR), Carbuccia, Nadine2 (AUTHOR), Popovici, Cornel9 (AUTHOR), Charafe-Jauffret, Emmanuelle10 (AUTHOR), Chaffanet, Max2 (AUTHOR), Birnbaum, Daniel2 (AUTHOR), Pakradouni, Jihane3 (AUTHOR), Bertucci, François1,2 (AUTHOR), Boher, Jean M.3,11 (AUTHOR), Sabatier, Renaud1,2 (AUTHOR) |
| Source: | European Journal of Cancer. Dec2021, Vol. 159, p205-214. 10p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
